Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Aspirin and hemostasis].

M M Samama1, I Elalamy

  • 1Service d'hématologie biologique, Hôtel-Dieu, Paris, France.

La Revue De Medecine Interne
|April 14, 2000
PubMed
Summary
This summary is machine-generated.

Low-dose aspirin irreversibly inhibits platelet cyclooxygenase, significantly reducing vascular death and heart attack recurrence. Understanding its mechanism confirms aspirin

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Thrombotic microangiopathy, DIC-syndrome and COVID-19: link with pregnancy prothrombotic state.

The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians·2020
Same author

Anticoagulants in frail patients. Seven situations at risk.

Journal de medecine vasculaire·2018
Same author

Meeting Report EuroG20 Meeting on Cancer-Associated Thrombosis (CAT) Bergamo, Italy 7 April 2016.

Cancer investigation·2018
Same author

Physicians' decision about long-term thromboprophylaxis in cancer outpatients: CAT AXIS, a case vignette study on clinical practice in France.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2018
Same author

Real-Life Peak and Trough Dabigatran Plasma Measurements over Time in Hospitalized Geriatric Patients with Atrial Fibrillation.

The journal of nutrition, health & aging·2018
Same author

Prevention and treatment of cancer-associated thrombosis in France: A national survey among vascular disease and supportive care specialists.

Journal de medecine vasculaire·2017
Same journal

[Abdominal pain, fever and arthralgia in a 49-year-old woman].

La Revue de medecine interne·2026
Same journal

[Cardiorespiratory functional disorders: A transnosologic approach].

La Revue de medecine interne·2026
Same journal

[Diagnostic evaluation for suspected polycythemia].

La Revue de medecine interne·2026
Same journal

Heart involvements in systemic sclerosis beyond pulmonary hypertension: From conduction, rhythm and function defects to coronary artery disease.

La Revue de medecine interne·2026
Same journal

[Acute intermittent porphyria: When diagnostic errance jeopardizes patient health].

La Revue de medecine interne·2026
Same journal

Autosomal dominant polycystic kidney disease: Current perspectives in 2026.

La Revue de medecine interne·2026
See all related articles

Area of Science:

  • Pharmacology and Cardiovascular Medicine

Background:

  • Aspirin's antithrombotic effects are well-established, evolving over the last 25 years.
  • Prostaglandin H synthetase (PGHS) is a key enzyme with two isoforms, PGHS-1 and PGHS-2.
  • Aspirin irreversibly acetylates PGHS-1, inhibiting thromboxane A2 production.

Purpose of the Study:

  • To elucidate the mechanism of aspirin's antithrombotic action.
  • To understand aspirin's efficacy in reducing vascular events.
  • To explore potential aspirin resistance and its implications.

Main Methods:

  • Investigating the irreversible acetylation of platelet cyclooxygenase by aspirin.
  • Analyzing the dose-dependent inhibition of thromboxane A2 synthesis.
  • Reviewing clinical studies, including the ISIS 2 trial, on aspirin's antithrombotic efficacy.

Related Experiment Videos

Main Results:

  • Very low aspirin doses (30-50 mg/day) achieve >95% inhibition of thromboxane A2 synthesis within 2-3 days.
  • The ISIS 2 study demonstrated significant risk reduction in vascular death and infarct recurrence.
  • Clinical efficacy correlates with the dose required for enzyme acetylation and thromboxane A2 inhibition.

Conclusions:

  • Aspirin has a secure role in antithrombotic therapy, supported by strong clinical evidence.
  • Understanding the mechanism of action validates its therapeutic use.
  • Aspirin may possess novel non-hemostatic applications beyond thrombosis.